Apollo Hospitals Creates History with India’s First SAPIEN 3 Ultra RESILIA Valve
Apollo Hospitals Creates History with India’s First SAPIEN 3 Ultra RESILIA Valve
A Major Breakthrough in the Treatment of Severe Aortic Stenosis
Chennai, September 4, 2025: Apollo Hospitals, Chennai, has achieved a historic milestone by performing the country’s first implantation of the Edwards SAPIEN 3 Ultra RESILIA transcatheter aortic valve (TAVI). This next-generation valve is designed to last longer and reduce the need for repeat procedures, transforming outcomes for patients suffering from severe aortic stenosis. The inaugural procedure was performed by Dr. G. Sengottuvelu, Senior Interventional Cardiologist and Head of Structural Interventions at Apollo Hospitals, Chennai.
The first case involved a 70-year-old patient with severe calcific tricuspid aortic stenosis and a prior coronary stent, who was considered high-risk for open-heart surgery. With the advanced RESILIA technology, doctors were able to provide a safe, minimally invasive, and durable solution.
Ms. Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Group, said, “Apollo Hospitals has always pioneered advanced cardiac care in India. The introduction of the SAPIEN 3 Ultra RESILIA valve is a significant milestone as it offers patients access to a minimally invasive solution with proven durability. By bringing such global innovations to India, we are ensuring that our patients receive the same standard of care as anywhere in the world, with the added assurance of better long term outcomes. This achievement reaffirms Apollo’s role as a trusted destination for the most complex cardiac interventions in the country.”
Dr. G. Sengottuvelu, Senior Interventional Cardiologist and Head of Structural Interventions, Apollo Hospitals, Chennai, said, “This procedure marks a new chapter in cardiac care in India. The SAPIEN 3 Ultra RESILIA valve is built to resist calcification and extend durability, which means our patients can expect safer outcomes and a longer life for their replacement valve. The unique RESILIA tissue technology significantly reduces structural valve deterioration (SVD) and paravalvular leak (PVL), two of the biggest challenges in valve therapy, allowing us to treat even high-risk patients with greater confidence and improved long-term results.”
The SAPIEN 3 Ultra RESILIA valve represents the latest evolution in TAVI technology, incorporating advanced tissue treatment that blocks calcification, stabilises valve tissue, and enables dry storage. Clinical studies have shown over 99% freedom from valve deterioration at 8 years, making it the most durable option available for patients worldwide. For Indian patients, this breakthrough means faster recovery, reduced risks of complications, and a safer long-term pathway to healthier living.
